Maduck Sean sold $3.9M of CORT

Maduck Sean (See Remarks) sold 30,955 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $125.58 ($125.47–$126.06, $3.89M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Aug 27, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The transaction is a routine insider sale; limited trading relevance.

02

Market read

Small‑scale insider sale; unlikely to affect stock price significantly.

03

What to watch

Potential upcoming clinical trial results or regulatory news not disclosed here.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑08‑25

Background

Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Officer Maduck Sean sold 30,955 shares for $3.9M via a 10b5‑1 plan on 2026‑08‑25.

Expected impact

Potential slight downward pressure; unlikely to move price materially.

Evidence & confidence

Sale amount is under $5M and represents a small fraction of total shares; market may view it as routine.

Market effects

Minimal impact on the pharmaceutical sector; insider sales are common.

No regional effect.

Not globally relevant.

Counterpoint

The sale could be a portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Corcept Therapeutics Inc

    Biopharmaceutical company developing cortisol‑targeting therapies.

  • Maduck Sean

    Company officer who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.